Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two ...

The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows. Three years later, ...

Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts.

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

HC Wainwright reaffirmed their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently ...

In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Sell rating on Harmony Biosciences Holdings (HRMY – Research Report), with a price target of $32.00 ...

Harmony Biosciences (NASDAQ:HRMY) just reported results for the second quarter of 2024. Harmony Biosciences reported earnings per share of $1.05. This was above the analyst estimate for EPS of -6 ...